The most recent statement that Sarepta Therapeutics, INC made with the Securities and Exchange Commission (SEC) revealed that during the third quarter, the Treasurer of the State of North Carolina increased their holdings in Sarepta Therapeutics, INC (NASDAQ: SRPT) by a total of 40.9%.
The corporation had a total of 50,147 shares of stock in the biotechnology company after the completion of the transaction, having acquired an additional 14,550 shares during the period in question.
The Treasurer of the State of North Carolina held approximately 0.06% of the shares in Sarepta Therapeutics at the end of the most recent reporting period, which had a market value of $5,543,000 at the time.
Recent developments have resulted in shifts in the proportion of SRPT common stock held by various other institutional investors and hedge funds.
PNC Financial Services Group INC increased the percentage of ownership it holds in Sarepta Therapeutics by 189.1% during the first three months of 2018.
PNC Financial Services Group INC has increased its holdings of 3,783 shares, bringing its total number of shares in the biotechnology business up to 5,784 and worth $452,000.
This represents an increase from their previous holdings.
A brand-new investment worth a total of $185,000 was made in the stock of Sarepta Therapeutics by the Healthcare of Ontario Pension Plan Trust Fund during the first three months of 2018.
During the first three months of 2018, MetLife Investment Management LLC made a new investment in the pharmaceutical company Sarepta Therapeutics.
This investment was for a total of $421,000. Great West Life Assurance Company of Canada increased the amount of stock it owned in Sarepta Therapeutics by 6.6% over the first three months of 2018. Great West Life Assurance Co now owns 4,541 shares of the biotechnology company’s stock, which are currently valued at $377,000 after making an additional purchase of 281 shares during the period in question.
Last but not least, during the first three months of 2018, Dimensional Fund Advisors LP made an increase of 12.3% in the Sarepta Therapeutics stock it owned.
At the moment, Dimensional Fund Advisors LP has a direct ownership stake of 179,294 shares of the biotechnology company’s stock. Following the purchase of an additional 19,660 shares during the period in question, the value of the stock has increased to $14,007,000.
At present, 87.31% of the company’s shares are owned by hedge funds and other types of institutional investors.
On Monday, trading began under the ticker symbol “NASDAQ: SRPT” for $119.00.
The company’s current price is $113.83, which is the moving average of the price over the previous two hundred days, while the price over the last fifty days is $124.34, which is the moving average of the price.
There is a ratio of 3.58 debt to equity, a 3.99 quick ratio to current ratio, and a 4.36 current ratio to debt.
The price of Sarepta Therapeutics, INC reached a low of $61.28 over the past year, while the company reached a high of $134.08 over the same period.
The company has a price-to-earnings ratio of -14.49, a market capitalization of $10.45 billion, and a beta value of 0.98.
The negative price-to-earnings ratio indicates that the company is trading at a discount.
Additional information regarding Sarepta Therapeutics includes that Director Stephen Mayo sold 858 shares of the company’s stock on November 17.
This piece of information was uncovered on November 17.
The price at which each share was sold was a weighted average of $109.92, which brought the total amount of money transacted to $94,311.36.
Because of the sale, the director now directly owns 6,387 shares of the company.
Based on the current market price, these shares have a value of approximately 702,059.04 dollars.
Additional information regarding the transaction can be found in a document sent to the SEC and is now available online. 6.40 company insiders own a percent of the total shares currently outstanding.
Many scientific organizations have held meetings where SRPT was discussed as a topic of interest.
BTIG Research upgraded its price objective for the stock of Sarepta Therapeutics from $125.00 to $160.00 and assigned the stock a “buy” rating in a research report released on Thursday, December 22.
BTIG Research also gave the stock of Sarepta Therapeutics a “buy” rating. Credit Suisse Group upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating in a research report published on Tuesday, January 10.
Despite this upgrade, the firm’s target price for the stock remained the same at $101.00.
The price objective that Robert W.
Baird has set for Sarepta Therapeutics has increased from $110.00 to $152.00, as stated in a research report published on November 3.
Before this, the price goal was set at $110.00. Goldman Sachs Group upgraded their recommendation for Sarepta Therapeutics from “buy” to “strong buy” in a report on the company’s market performance published on November 3.
In addition, the company pushed its price target up to $152.00. Cantor Fitzgerald increased their price target for Sarepta Therapeutics from $150.00 to $174.00 in a research report published on Tuesday, December 13.
The agenda was complete, and this was the final and most important item.
Eight equity research professionals rated the company as a buy, while only three gave it a hold rating.
Eight of the professionals made the recommendation to buy the company.
According to Bloomberg, the general opinion regarding Sarepta Therapeutics is that investors should “moderately buy” the company’s stock, and the price target for the stock is currently set at $150.14.
The biopharmaceutical company known as Sarepta Therapeutics, INC has advanced to its commercial development stage.
It is currently focusing its efforts on the research and development of treatments for rare diseases.
The current location of the company’s headquarters, which was established on July 22, 1980, is in Cambridge, which is found in the state of Massachusetts.
Leave a comment